JenKem Technology

About JenKem Technology

JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEGs) derivatives and PEG raw materials, related custom PEG and co-polymer synthesis, and pegylation services. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through GMP commercial scale. Activated PEGs are especially useful in drug delivery and targeted diagnostics, as cross-linking agents or spacers between two chemical entities, whereas mono-functional PEGs prevent bridging reactions which can affect the PEGylation of certain compounds. Activated PEG derivatives with different terminal functional groups are widely used in the PEGylation of peptides, proteins, antibodies, small molecules, like folate, mannose, pro-drugs or oligonucleotides, cells, nanoparticles and virus particles, or surfaces. Multi-arm PEG derivatives are largely employed in the formation of hydrogels. PEG hydrogels are used in controlled release of therape...

  • US
  • 2015
    On CPhI since
Contact info

Products from JenKem Technology

  • A10022-1, 8ARM(TP)-SH-10K,1g

    Product A10022-1, 8ARM(TP)-SH-10K,1g

    8arm PEG Thiol (tripentaerythritol), MW 10000
  • JenKem Technology and Merck Announce Distribution Agreement

    Product JenKem Technology and Merck Announce Distribution Agreement

    BEIJING, Sept. 19, 2016 /PRNewswire-iReach/ -- JenKem Technology and the life science business of Merck are pleased to announce a collaboration agreement for the distribution of select JenKem Technology high quality polyethylene glycol (PEG) products for biomedical applications by Merck.

    http://www.ireachcontent.com/news-releases/jenkem-technology-and-merck-announce-distribution-agreement-593959171.html  
     
    JenKem Technology's PEG products are widely used for drug delivery and hydrogel manufacturing in the pharmaceutical, biotechnology, medical device, diagnostics, and emerging chemical specialty markets. The distribution agreement allows Merck to introduce and market JenKem Technology's portfolio of PEG products to their existing customer base. Merck's global distribution infrastructure will allow small volume PEG users convenient access to select JenKem® PEG products, such as Y-Shape PEGs, Methoxy PEGs, and Monodisperse PEGs for PEGylation, Homobifunctional PEGs, Heterobifunctional and Multi-arm Heterobifunctional PEG linkers for ADCs and other applications, Multi-arm PEGs for hydrogels, and Biodegradable PEG Co-Polymers for controlled release drug delivery. JenKem® PEG products sold by Merck will contain the statement "Product of JenKem Technology" on the product label whenever possible and on Merck's website, www.sigma-aldrich.com, and other promotional materials. JenKem Technology's products will be marketed under the Aldrich® brand in Merck's Sigma-Aldrich catalog.

    "It is a great opportunity to partner with Merck to allow JenKem® PEGs to become more widely available to researchers in the biomedical field. The arrangement with Merck allows us to leverage Merck's substantial relationships and infrastructure within the biomedical and related industries" says JenKem Technology's VP of Business Development, Dr. Mark Frishberg.

    With strategic international locations, Merck will offer JenKem Technology worldwide coverage, local sales force, and superior logistics. Merck will hold inventory of JenKem PEGS and ship direct using their excellent logistics systems. JenKem Technology Co., Ltd. and JenKem Technology USA, Inc., the sales subsidiary of JenKem Technology Co. Ltd., will continue to provide sales of PEG products and PEGylation services in small research scale where a customer chooses to work directly with JenKem Technology, and for bulk and commercial scale non-GMP and GMP grade products. Products distributed by JenKem Technology Co. Ltd. and JenKem Technology USA, Inc. will continue to be shipped to the customer directly from the JenKem Technology Co. Ltd.'s manufacturing facilities in Beijingand Tianjin P.R. China.

    Contact:

    JenKem Technology

    Company Information and Sales Related Inquiries:

    Contact: Daniela Hutanu, PhD

    Manager, Sales and Marketing

    JenKem Technology USA

    4105 W. Spring Creek Pkwy, Suite #606B

    Plano, TX 75024, USA

    Phone: +1-972-673-0603

    Email: [email protected]

    Website: www.jenkemusa.com

    Custom Capabilities and Confidentiality Agreements:

    Contact: Mark Frishberg, PhD

    VP of Business Development

    Phone: +1-707-322-3035

    Email: [email protected]        

    Merck

    Jansen Xu 徐锦承

    Head of Communications, Performance Materials and Life Science

    Merck Holding China

    Tower 2, No.88 Chenhui Road

    Shanghai,201203, China

    Tel: +86 (0)21 2033 8299

    E-mail: [email protected]

    www.merck.com.cn or www.merckmillipore.com
  • PEGylation Services

    Product PEGylation Services

    JenKem Technology’s dedicated and experienced technical support group can help you identify the right high quality PEG derivatives for your pegylation needs. Currently JenKem Technology provides two pegylation service models:

    Service model 1. PEGylation services provided as a regular end-product.
    JenKem Technology will PEGylate your molecule and deliver your PEGylated product with a certificate of analysis, as a regular end-product, for further testing at your site. This is recommended for an initial evaluation of PEGylation approaches.

    Service model 2. Complete PEGylation method development service.
    Under this service model, JenKem will provide your PEGylated sample, as well as the complete PEGylation method development package, including all developed analytical methods for characterization of your PEGylated product, up to pre-clinical stage. The PEGylation processes developed by JenKem Technology are easily scalable and transferable and consist of the following main steps:

    Phase 1: JenKem delivers PEGylated compounds to the customer for pharmaceutical analysis and provides a detailed report including PEGylation reaction conditions, separation and purification processes, and analytical methods for the PEGylated compounds.
    PEG reagent screeningPEGylation reaction conditions screeningSeparation and purification process development
    Analytical method development (HPLC, SDS-PAGE, GPC, and other qualitative or quantitative methods for analysis of PEGylated products)
    Synthesis, characterization and delivery of PEGylated molecule

    Phase 2: JenKem prepares the pre-clinical data of PEGylated compounds and chooses the best PEGylated compounds according to the pharmaceutical data.

    Quality specification study of PEGylated moleculesFormulation study of PEGylated molecules
    Pharmacodynamics study of PEGylated molecules
    Toxicology study of PEGylated molecules 
    Please contact our technical support group at [email protected] for more details on our PEGylation services.